NYSE: NNVC - NanoViricides, Inc.

Yield per half year: -10.74%
Dividend yield: 0.00%
Sector: Healthcare

Share chart NanoViricides, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About NanoViricides, Inc.

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications.

more details
The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2005-10-26
ISIN US6300873022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.nanoviricides.com
Цена ао 1.27
Change price per day: 0% (1.33)
Change price per week: +20.91% (1.1)
Change price per month: +1.53% (1.31)
Change price per 3 month: +10.83% (1.2)
Change price per half year: -10.74% (1.49)
Change price per year: +14.66% (1.16)
Change price per 3 year: -27.72% (1.84)
Change price per 5 year: -80.06% (6.67)
Change price per year to date: -11.92% (1.51)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.99 7
P/E 0 0
EV/EBITDA -2.32 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -55.81 0
ROE, % -63 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0122 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 4.83 1
Yield EPS, % -79.02 0
Total: 0.2
More

Institutions Volume Share, %
Vanguard Group Inc 458416 3.89
Blackrock Inc. 159297 1.35
Compagnie Lombard Odier SCmA 150000 1.27
Geode Capital Management, LLC 109489 0.93
Renaissance Technologies, LLC 78500 0.67
Bridgeway Capital Management, Inc. 59039 0.5
State Street Corporation 41906 0.36
Royal Bank of Canada 30535 0.26
Northern Trust Corporation 29664 0.25
Stifel Financial Corporation 21200 0.18



Head Job title Payment Year of birth
Dr. Anil R. Diwan Ph.D. Executive Chairman, President, CEO & Secretary 400k 1959 (66 years)
Dr. Randall W. Barton Ph.D. Chief Scientific Officer N/A 1947 (78 years)

Address: United States, Shelton. CT, 1 Controls Drive - open in Google maps, open in Yandex maps
Website: https://www.nanoviricides.com